NCT03202628 · OUTCOME

Change in Minimal Residual Disease (MRD) in Bone Marrow Assessed by Flow Cytometry

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma · Source last updated 2023-09-21

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline up to 1 year from initiation of maintenance therapy

What was measured

The proportion of patients who achieve MRD negative status will be estimated by the number of patients who are MRD negative divided by the total number of evaluable patients who achieve a stringent complete response (sCR) or complete response (CR). Exact binomial 95% confidence intervals for the true MRD negative rate will be calculated.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The proportion of patients who achieve MRD negative status will be estimated by the number of patients who are MRD negative divided by the total number of evaluable patients who achieve a stringent complete response (sCR) or complete response (CR). Exact binomial 95% confidence intervals for the true MRD negative rate will be calculated.
reporting Status: NOT_POSTED
time Frame: Baseline up to 1 year from initiation of maintenance therapy
title: Change in Minimal Residual Disease (MRD) in Bone Marrow Assessed by Flow Cytometry
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice